Results 51 to 60 of about 2,963,117 (406)

Genome-Wide Association Study Identifies Loci for Liver Enzyme Concentrations in Mexican Americans: The GUARDIAN Consortium. [PDF]

, 2019
ObjectivePopulations of Mexican American ancestry are at an increased risk for nonalcoholic fatty liver disease. The objective of this study was to determine whether loci in known and novel genes were associated with variation in aspartate ...
Chen, Yii-Der I, Fingerlin, Tasha E, Goodarzi, Mark O, Guo, Xiuqing, Langefeld, Carl D, Norris, Jill M, Palmer, Nicholette D, Raffel, Leslie J, Rotter, Jerome I, Taylor, Kent D, Wagenknecht, Lynne E, Wang, Nan, Watanabe, Richard M, Williams, Adrienne H, Xiang, Anny H, Young, Kendra A   +15 more
core   +2 more sources

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Hepatology, 2019
Over the past 2 decades, nonalcoholic fatty liver disease (NAFLD) has grown from a relatively unknown disease to the most common cause of chronic liver disease in the world.
Z. Younossi, F. Tacke, M. Arrese, Barjesh Chander Sharma, I. Mostafa, E. Bugianesi, V. Wai‐Sun Wong, Y. Yılmaz, J. George, Jian-Gao Fan, M. Vos   +10 more
semanticscholar   +1 more source

Targeting Thyroid Hormone/Thyroid Hormone Receptor Axis: An Attractive Therapy Strategy in Liver Diseases

Frontiers in Pharmacology, 2022
Thyroid hormone/thyroid hormone receptor (TH/TR) axis is characterized by TH with the assistance of plasma membrane transporters to combine with TR and mediate biological activities.
Qianyu Tang, Min Zeng, Linxi Chen, Nian Fu, Nian Fu   +4 more
doaj   +1 more source

DNA Hydroxymethylation at the Interface of the Environment and Nonalcoholic Fatty Liver Disease. [PDF]

, 2019
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver disorders among adults, children, and adolescents, and a growing epidemic, worldwide.
Besaratinia, Ahmad, Tommasi, Stella
core   +1 more source

Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis [PDF]

, 2020
Background A non-invasive method to grade the severity of steatohepatitis and liver fibrosis is magnetic resonance imaging (MRI) based corrected T1 (cT1).
Banerjee, R, Banerjee, R, Bell, J.D., Bell, J.D., Hemingway, H., Hemingway, H., Hingorani, A.D., Hingorani, A.D., Kelly, M., Kelly, M., McGonigle, J., McGonigle, J., Neubauer, S., Neubauer, S., Nicholls, R.C., Nicholls, R.C., Parisinos, C.A., Parisinos, C.A., Patel, R.S., Patel, R.S., Thomas, E.L., Thomas, E.L., Wilman, H., Wilman, H., Yaghootkar, H., Yaghootkar, H.   +25 more
core   +3 more sources

Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression [PDF]

, 2018
The complete mechanism accounting for the progression from simple steatosis to steatohepatitis in nonalcoholic fatty liver disease (NAFLD) has not been elucidated.
Avolio, Carlo, Bellanti, Francesco, Blonda, Maria, di Bello, Giorgia, Facciorusso, Antonio, Iannelli, Giuseppina, Iuliano, Luigi, Poli, Giuseppe, Serviddio, Gaetano, Tamborra, Rosanna, Vendemiale, Gianluigi, Villani, Rosanna   +11 more
core   +2 more sources

Non-alcoholic fatty liver disease: Definition and subtypes

Clinical and Molecular Hepatology, 2022
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide, with a global prevalence of approximately 30%. However, the prevalence of NAFLD has been variously reported depending on the comorbidities.
S. Han, S. Baik, M. Kim
semanticscholar   +1 more source

Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced GeneSummary

Cellular and Molecular Gastroenterology and Hepatology, 2021
Background and Aims: Butyric acid is an intestinal microbiota-produced short-chain fatty acid, which exerts salutary effects on alleviating nonalcoholic fatty liver disease (NAFLD).
Ze-Hua Zhao, Zi-Xuan Wang, Da Zhou, Yamei Han, Fengguang Ma, Zhimin Hu, Feng-Zhi Xin, Xiao-Lin Liu, Tian-Yi Ren, Feifei Zhang, Yaqian Xue, Aoyuan Cui, Zhengshuai Liu, Jinyun Bai, Yuxiao Liu, Genxiang Cai, Weitong Su, Xiaozhen Dai, Feng Shen, Qin Pan, Yu Li, Jian-Gao Fan   +21 more
doaj   +1 more source

Current treatment of non‐alcoholic fatty liver disease

Journal of Internal Medicine, 2022
Non‐alcoholic fatty liver disease (NAFLD) comprises a wide spectrum of pathologies ranging from non‐alcoholic fatty liver (NAFL), characterized by simple steatosis without inflammation, to non‐alcoholic steatohepatitis (NASH), characterized by steatosis ...
R. Paternostro, M. Trauner
semanticscholar   +1 more source

A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease

Gastro Hep Advances
Background and Aims: Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis are pressing public health problems occurring alongside the rising prevalence of obesity and diabetes.
Naim Alkhouri, Katherine Edwards, Mark Berman, Heather Finn, Rafael Escandon, Paul Lupinacci, Nicole Guthrie, Angie Coste, Jesus Topete, Mazen Noureddin   +9 more
doaj   +1 more source